Please upgrade your browser.
The FDA has approved sunitinib (Sutent) for use as an adjuvant therapy in patients with renal cell carcinoma (RCC) who have received nephrectomy and are high risk for recurrence.
We're seeking your input on the planning of a large patient education meeting that would span two days and include presentations from leading experts from the major institutions...
The Kidney Cancer Association (KCA) invites proposals from young investigators for the 2018-2019 grant cycle. Young Investigator Award (YIA) abstracts are being accepted beginning October 30, 2017.
Kidney Cancer Research (KCRP) has been funded by the CDMRP for many years under various programs including the Peer Reviewed Medical Research Program, Tuberous Sclerosis Complex Research Program, and, most recently, by the Peer Reviewed Cancer Research Program (PRCRP). From FY10 through FY16, the PRCRP invested over $9.8M in kidney cancer research. In FY17 the US Congress directed $10M to kidney cancer research in the DoD appropriation, thus establishing the Kidney Cancer Research Program.
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact...
The Dennis C. Baylor “BIG LUV” Kidney Cancer Foundation is proud to Announce that we will be hosting an elegant Evening with a purpose.
The FY17 Defense Appropriations Act provides $10 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support United States Army Medical Research Acquisition Activity (USAMRAA). As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).
Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.
Amgen Inc. AMGN, -1.37% and Allergan AGN, -1.08% said Thursday that the Food and Drug Administration has approved their biosimilar version of Roche's Avastin for five types of cancer.
Copies of NCCN's treatment guidelines for patients are available in several languages at this week's ESMO meeting in Madrid, Spain.
|Powered by NeonCRM|